Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy
Author:
Affiliation:
1. Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2. UC San Diego Department of Neurosciences, Parkinson and Other Movement Disorder Center, La Jolla, CA, USA
Funder
not funded
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/13543784.2018.1460356
Reference120 articles.
1. Progressive Supranuclear Palsy
2. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
3. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
4. The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases
5. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies;Expert Opinion on Investigational Drugs;2023-07-03
2. Why Therapeutic Trials Fail in Primary Tauopathies;Movement Disorders;2023-01-20
3. Passive tau-based immunotherapy for tauopathies;Handbook of Clinical Neurology;2023
4. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders;Molecular Neurobiology;2022-12-23
5. Clinical Spectrum of Tauopathies;Frontiers in Neurology;2022-07-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3